Mead Johnson Milks Growth Of Emerging Market Middle Class
This article was originally published in PharmAsia News
Mead Johnson sees growth in emerging markets largely because per-birth consumption of infant formula is well below developed regions. The firm invests nearly $100 million in research to provide the pediatric nutritionals innovation sought by parents, VP of Investor Relations Kathy Ann MacDonald says.
You may also be interested in...
Mead Johnson Upbeat On China Outlook After Series Of Setbacks
The infant nutritionals firm has put a poorly timed price increase behind it and is optimistic about the effects of a Hong Kong limit on formula exports on China sales. Additionally, a recall of Danone baby nutrition products in Asia is expected to benefit Mead Johnson over the next 9 to 12 months.
In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.